Literature DB >> 30282492

Management of advanced heart failure: a review.

Eran Kalmanovich1, Yohan Audurier2, Mariama Akodad1, Marc Mourad3,4, Pascal Battistella1, Audrey Agullo1, Philippe Gaudard3,4, Pascal Colson3,4, Philippe Rouviere5, Bernard Albat5, Jean-Etienne Ricci6, François Roubille1,4.   

Abstract

INTRODUCTION: Heart failure (HF) has become a global pandemic. Despite recent developments in both medical and device treatments, HF incidences continues to increase. The current definition of HF restricts itself to stages at which clinical symptoms are apparent. In advanced heart failure (AdHF), it is universally accepted that all patients are refractory to traditional therapies. As the number of HF patients increase, so does the need for additional treatments, with an increased proportion of patients requiring advanced therapies. Areas covered: This review discusses extensive evidence for the effect of medical treatment on HF, although the data on the effect on AdHF is scare. Authors review the relevant literature for treating AdHF patients. Furthermore, mechanical circulatory devices (MCD) have emerged as an alternative to heart transplantation and have been shown to enhance quality of life and reduce mortality therefore authors also review the current literature on the different MCD and technologies. Expert commentary: More patients will need advanced therapies, as the access to heart transplantation is limited by the number of available donors. AdHF patients should be identified timely since the window of opportunities for advanced therapy is narrow as their morbidity is progressive and survival is often short.

Entities:  

Keywords:  Advanced heart failure; cardiogenic shock; mechanical circulatory assist devices; percutaneous mechanical circulatory devices

Mesh:

Year:  2018        PMID: 30282492     DOI: 10.1080/14779072.2018.1530112

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  1 in total

1.  Long-Term Mortality and Morbidity Related to Congestive Heart Failure with Reduced Ejection Fraction (CHFrEF) in Palestinian Patients Maintained on Submaximal Sacubitril/Valsartan Doses: A Pilot Study.

Authors:  Raed Aqel; Tareq Z Alzughayyar; Sadi A Abukhalaf; Rami A Misk; Jihad Samer Zalloum
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2021-12-28       Impact factor: 1.636

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.